PTC
INDV icon

Petrus Trust Company’s Indivior Pharmaceuticals INDV Stock Holding History

Petrus Trust Company’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-128,277
Closed -$1.25M – 663
2024
Q3 		$1.25M Buy
+128,277
New +$1.5M 0.12% 26

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Petrus Trust Company's INDV Position: Q4 2024 in Review

Petrus Trust Company sold out of Indivior Pharmaceuticals (INDV) in Q4 2024, closing a stake of 128,277 shares — an estimated $1.25M sold.

Petrus Trust Company first reported a position in INDV in Q3 2024 and held it in 1 quarter. The position peaked at $1.25M in Q3 2024. 113 funds tracked by Wall St. Rank hold INDV as of Q4 2024.

  • Petrus Trust Company reported no remaining Indivior Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Petrus Trust Company sold 128,277 Indivior Pharmaceuticals shares in Q4 2024, an estimated $1.25M.
  • Petrus Trust Company first reported a position in Indivior Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Petrus Trust Company's Indivior Pharmaceuticals position peaked at $1.25M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2024.

Based on Petrus Trust Company's 13F filing for Q4 2024, filed 14 Feb 2025.